Kinase inhibitor ALW-II-41-27 suppresses EphA2 kinase activity in NSCLC cells by blocking the ATP-binding section of the kinase domain, with an IC50 value of 11 nM, reducing cell viability and triggering apoptosis in culture. This evidence concerns the gene EPHA2 and non-small cell lung carcinoma.